Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Adolescent, Adult, Aged, Antineoplastic Agents, adverse effects, therapeutic use, Arsenicals, Child, Disease-Free Survival, Female, Follow-Up Studies, Humans, Iran, Leukemia, Promyelocytic, Acute, drug therapy, Male, Middle Aged, Oxides, Remission Induction, Survival Analysis

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      The long-term follow-up results of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy show high cure rates. Several studies have shown high efficacy of single-agent arsenic trioxide in newly diagnosed APL. However, long-term follow-up results are needed. One hundred ninety-seven patients with newly diagnosed APL were treated with arsenic trioxide 0.15 mg/kg daily intravenous infusion until complete remission (CR). After achieving CR, the patients received one to four more courses of therapy with arsenic trioxide as consolidation and were observed with reverse-transcriptase polymerase chain reaction studies from peripheral blood (to detect of minimal residual disease) every 3 months or until relapse or death. The morphologic CR rate was 85.8%. The most common cause of remission failure was early death owing to APL differentiation syndrome (13.2%). The most important prognostic factor for early mortality was a high WBC count at presentation. The 5-year disease-free survival (DFS) rate was 66.7% ± 4% (SE). Relapse after 5 years in CR was rare. The 5-year overall survival (OS) rate by intention-to-treat analysis was 64.4% ± 4%. In patients who achieved CR, OS and DFS were identical. The long-term follow-up of newly diagnosed patients with APL treated with single-agent arsenic trioxide shows high rates of DFS and OS.

      Related collections

      Author and article information

      Journal
      21646615
      10.1200/JCO.2010.32.2107

      Comments

      Comment on this article